Samuel Jacob Klempner

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. David Tsai Ting · 1 shared grant, 2026 · strength 0.86
   • Grant High Resolution Dissection of Response Mechanisms to Chemoradiation in Gastrointestinal Cancers P01CA295486↗
2. William L. Hwang · 1 shared grant, 2026 · strength 0.86
   • Grant High Resolution Dissection of Response Mechanisms to Chemoradiation in Gastrointestinal Cancers P01CA295486↗
3. Theodore Sunki Hong · 1 shared grant, 2026 · strength 0.86
   • Grant High Resolution Dissection of Response Mechanisms to Chemoradiation in Gastrointestinal Cancers P01CA295486↗
4. Andrew Eugene Hendifar · 2 shared papers, 2019–2021 · strength 0.19
   • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
   • Paper A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic ca… DOI 10.1016/j.ebiom.2018.12.060↗
5. Timothy Lewis Cannon · 1 shared paper, 2021 · strength 0.11
   • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
6. Emanuel F. Petricoin · 1 shared paper, 2021 · strength 0.11
   • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
7. Isha Singh · 1 shared paper, 2021 · strength 0.11
   • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
8. Eric Andrew Collisson · 1 shared paper, 2021 · strength 0.11
   • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
9. Eileen Mary O'Reilly · 1 shared paper, 2021 · strength 0.11
   • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
10. Brian Matthew Wolpin · 1 shared paper, 2021 · strength 0.11
    • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
11. Vivek Subbiah · 1 shared paper, 2021 · strength 0.11
    • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
12. Michael Jon Pishvaian · 1 shared paper, 2021 · strength 0.11
    • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
13. Andrea Wang‐Gillam · 1 shared paper, 2021 · strength 0.11
    • Paper Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted an… DOI 10.1200/po.20.00494↗
14. Veronica Placencio-Hickok · 1 shared paper, 2019 · strength 0.07
    • Paper A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic ca… DOI 10.1016/j.ebiom.2018.12.060↗
15. Simon K. Lo · 1 shared paper, 2019 · strength 0.07
    • Paper A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic ca… DOI 10.1016/j.ebiom.2018.12.060↗
16. Nicholas N. Nissen · 1 shared paper, 2019 · strength 0.07
    • Paper A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic ca… DOI 10.1016/j.ebiom.2018.12.060↗
17. Richard Tuli · 1 shared paper, 2019 · strength 0.07
    • Paper A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic ca… DOI 10.1016/j.ebiom.2018.12.060↗
18. Arsen Osipov · 1 shared paper, 2019 · strength 0.07
    • Paper A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic ca… DOI 10.1016/j.ebiom.2018.12.060↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.